Shanghai Henlius Biotech's biosimilar to Roche's Rituxan has been approved by China’s NMPA, the first biosimilar approved in China. Shanghai Henlius, which was set up in 2010 as a JV between Shanghai Fosun Pharma and US-based Henlius, focuses on novel and biosimilar mAbs. In a China Phase III trial, the Henlius biosimilar showed it matched the efficacy of the Roche original in patients with CD20-positive non-Hodgkin lymphoma. Ironically, Rituxan was the first monoclonal antibody approved for US use as a cancer treatment. More details....
Stock Symbols: (HK: 02196: SHA: 600196)
Share this with colleagues: